Proactive - Interviews for investors

ATOME PLC (AIM:ATOM) CEO Olivier Mussat talked with Proactive's Stephen Gunnion about the appointment of Switzerland-based Casale as the engineering, procurement, and construction contractor for its 145-megawatt Villeta project in Paraguay.

Mussat emphasised Casale's crucial role as the EPC contractor, highlighting their expertise in mid-sized fertilizer plants and legacy in ammonia technology. "They’ve delivered over 300 ammonia and fertiliser plants, making them a natural partner for us," Mussat said.

He also discussed the appointment of Sam Mackilligan, who brings invaluable project management experience and deep familiarity with the Villeta project. The conversation covered the challenges of project financing, with positive signals emerging due to Paraguay’s new investment grade status. Despite the delays, Mussat expressed optimism, stating, "We are seeing all the good signals... a path to FID is clear."

As ATOME heads into 2025, its focus remains on securing financing to advance Villeta. The company envisions this green industrial project as a groundbreaking model for future sustainable developments.

For more insights, visit Proactive's YouTube channel for updates on ATOME PLC and other pioneering companies. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content!

#ATOMEPLC #GreenEnergy #GreenFertilizer #VilletaProject #OlivierMussat #CasaleEngineering #ProjectFinancing #Sustainability #HydrogenEconomy #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief scientific officer, Professor Lindy Durrant, talked with Proactive's Stephen Gunnion about the company's groundbreaking results from the SCOPE trial. The trial focuses on SCIB1 in combination with double checkpoint inhibitors ipilimumab and nivolumab for advanced melanoma.

Professor Durrant highlighted that cohort one demonstrated an 84% disease control rate, with 72% of tumours shrinking and 20% completely clearing. The most exciting outcome was an 80% progression-free survival rate at six months, signalling durable and significant tumour control. This data underscores the potential for longer-term benefits in advanced cancer therapy.

She emphasised the importance of progression-free survival as a predictor for overall survival and explained its role as the endpoint for upcoming phase two/three registration studies. The discussion also covered the next steps in the trial, updates on iSCIB1+, and the company's other programs, including Modi-1 and their antibody platform.

Quoting Professor Durrant: “Once we get control of the tumour, we seem to maintain control.”

Watch the full interview for insights into Scancell's innovative approaches to cancer treatment.

Visit Proactive's YouTube channel for more videos, and don't forget to like, subscribe, and enable notifications for future updates.

#Scancell #SCIB1 #CancerResearch #AdvancedMelanoma #CheckpointInhibitors #Immunotherapy #ProgressionFreeSurvival #SCOPETrial #Modi1 #Oncology #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

North Bay Resources Inc. (OTC:NBRI) CEO Jared Lazerson talked with Proactive's Stephen Gunnion about the company's latest significant achievement—producing its first gold concentrates at the Bishop Gold Mill. Lazerson detailed the milestone, explaining that gold was recovered from the Fran Gold Project within just six weeks of ore delivery. "I've never heard of a mill startup happening so quickly," he shared.

The company's strategy to integrate its mine and mill operations is proving effective. Lazerson highlighted the smooth startup, the quality of equipment, and the strength of the team in achieving this milestone. He discussed the company's partnership with a refinery in Reno, Nevada, enabling efficient processing and revenue generation.

North Bay Resources is now focused on scaling operations, with rail shipments of additional ore expected shortly. The company anticipates increased production in early 2025, aided by favorable gold prices currently above $2,600 per ounce. Lazerson emphasized the company's cost-efficiency, targeting production costs between $500 and $800 per ounce. "We're putting some points on the board, and it's very exciting," he concluded.

For more updates on North Bay Resources and their developments, visit Proactive's YouTube channel. Don’t forget to like, subscribe, and enable notifications for future content.

#NorthBayResources #GoldProduction #MiningNews #FranGoldProject #GoldInvesting #MillStartup #PreciousMetals #GoldPrices #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

​​​​​​​Ideal Power Inc (NASDAQ:IPWR) CEO Daniel Brdar takes Proactive's Stephen Gunnion through the company’s third-quarter performance and its ongoing momentum. Brdar highlighted that Ideal Power is now collaborating with three major global automakers, including Stellantis, with two of them ranked among the top ten globally.

The company has also expanded its global distribution network with partners like RYOSHO in Japan and Z Corp in China, opening significant market opportunities. Ideal Power has received orders from tier-one automotive suppliers and initiated rigorous automotive qualification testing for its B-TRAN technology. Brdar emphasized the significance of advancing towards design wins, enabling integration into next-generation products, with potential volume ramp-ups expected in 2025.

Ideal Power ended the quarter with a strong cash position of $18.7 million, providing stability and enabling seamless execution of its roadmap.

For more insights, visit Proactive's YouTube channel for updates on Ideal Power Inc and other innovative companies. Don’t forget to like the video, subscribe, and enable notifications for future updates.

#IdealPower #BTRAN #ElectricVehicles #Semiconductors #AutomotiveInnovation #SustainableTechnology #Stellantis #TechAdvancements #IndustrialTechnology #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ilika PLC CEO Graeme Purdy takes Proactive's Stephen Gunnion through the company’s progress in the first half of the year, focusing on its Stereax and Goliath battery projects.

Purdy highlighted the significant advances in transferring Stereax production to Cirtec’s Massachusetts facility, with commissioning nearly complete. The company plans to begin delivering commercial battery samples to customers in 2025. He also noted progress on the Goliath solid-state batteries, emphasising safety advantages demonstrated in a recent nail penetration test video, showcasing the battery's superior stability.

Looking ahead, Ilika plans to unveil its D6 development milestone for Goliath, introducing larger pouch cells with a 10Ah capacity. These prototypes will undergo further testing and validation, with "A samples" expected by the end of 2025. Purdy assured investors of steady progress in the second half, maintaining full-year guidance and signalling upcoming updates.

Stay tuned for more insights and updates. Visit Proactive's YouTube channel for more videos, and don't forget to give this one a like, subscribe to the channel, and enable notifications for future content.

#IlikaPLC #BatteryInnovation #SolidStateBattery #Stereax #GoliathBattery #EnergyStorage #BatteryTechnology #ProactiveInvestors #RenewableEnergy #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF) managing director Tim Harrison joins Proactive’s Tylah Tully to discuss the results of a feasibility study for its rare earth oxide (REO) recycling facility in Belfast, UK.

The facility will process pre-consumer and end-of-life rare earth magnet scrap, supporting the UK’s green transition and supply chain independence.

Key findings include a post-tax net present value (NPV) of US$502 million (A$776 million), a 43.6% internal rate of return (IRR) and a capital payback period of 2.4 years.

Over 20 years, the facility is projected to generate US$2.12 billion (A$3.26 billion) in net revenue and US$1.78 billion (A$2.76 billion) in EBITDA.

With an annual throughput of 1,200 tonnes, it will produce 400 tonnes of high-purity REOs, such as neodymium and dysprosium oxides.

Located at Belfast Harbour, the plant will feature patented recycling technology by Ionic Technologies, requiring no mining and reducing environmental impacts.

Construction is expected by late 2026, with production starting in early 2027.

Supported by the UK Government’s Critical Minerals Strategy and partnerships with companies like Less Common Metals, the project advances a Western rare earth supply chain and aligns with global green energy goals. Ionic Rare Earths also plans to replicate this model internationally.

#ProactiveInvestors #RareEarths #ASX #OTC #Recycling #GreenEnergy #SupplyChain #Sustainability #UKManufacturing #IonicRareEarths #CircularEconomy #AdvancedManufacturing #BelfastFacility #CriticalMinerals #EnergyTransition #NetZero #Innovation #CleanTech #MagnetRecycling #WesternSupplyChain #PatentedTechnology #EnvironmentalImpact #GlobalExpansion

Amplia Therapeutics Ltd (ASX: ATX) CEO and managing director Chris Burns​​​​ joins Proactive’s Tylah Tully to discuss a preclinical research collaboration the company has entered into with Next&Bio, a drug screening company based in Seoul, South Korea.

This collaboration aims to evaluate the effects of Amplia’s focal adhesion kinase (FAK) inhibitors in combination with kRas inhibitors, a class of drugs under development for pancreatic cancer treatment.

Next&Bio, a subsidiary of Hk Kolmar Holdings, specialises in drug screening using patient-derived cancer cells cultivated under conditions that replicate the tumour environment.

These models allow accurate testing of potential drug efficacy, particularly in pancreatic cancer cases with oncogenic mutations.

The collaboration will test Amplia’s FAK inhibitors, such as narmafotinib (AMP945), against pancreatic cancer cells harbouring kRas mutations.

Narmafotinib, Amplia’s selective and potent FAK inhibitor, is currently in a Phase 2a trial evaluating its safety and efficacy in combination with gemcitabine and Abraxane®. The collaboration also investigates potential synergistic effects with kRas inhibitors, which could open new therapeutic opportunities for pancreatic cancer.

Burns highlighted the significance of testing the company’s FAK inhibitors in patient-derived cell systems to explore new commercial applications for combination therapies in pancreatic cancer.

#ProactiveInvestors #AmpliaTherapeutics #ASX #NextAndBio #FAKInhibitors #PancreaticCancer #DrugDevelopment #OncologyResearch #kRasInhibitors #CancerTherapy #Narmafotinib #PrecisionMedicine #CancerCells #Amplia #CancerResearch #ClinicalTrials #ASXNews #Pharmaceuticals #OncogeneResearch #MedicalInnovation #FAK #TargetedTherapy

Empire Energy Group Ltd (ASX:EEG, OTC:EEGUF) managing director Alex Underwood talked with Proactive’s Tylah Tully about the Carpentaria Pilot Project and its latest developments in the prolific Beetaloo Basin.

Underwood highlighted that the company had received environmental approval from the Northern Territory Government for its Environmental Management Plan. This is critical as Empire Energy moves into pilot production, which includes the drilling of more wells and the installation of a gas processing plant.

Discussing the new Carpentaria 5H well, Underwood explained that it would be the largest well the company has drilled to date.

He stated, “We are obviously very excited about the prospect of starting to generate revenue… The primary goal of the program is to be able to produce these wells over longer time periods, so we can get a good sense of how they produce over time.”

Empire Energy plans to install a gas processing plant and commence gas sales during the dry season in early Q2 of next year. The company has also estimated its gas resources at approximately 5.00 trillion cubic feet, demonstrating the commercial potential of its asset in the Beetaloo Sub-Basin.

#ProactiveInvestors #EmpireEnergy #ASX #OTC #CarpentariaPilotProject #EnvironmentalApproval #GasExploration #BeetalooBasin #NorthernTerritory #EnergyProjects #ASXNews #OilAndGas #GasProcessing #EnergyMarket #NaturalGas #McArthurPipeline #JobCreation #ManufacturingResurgence #GasSales #EnergyDevelopment #AustraliaEnergy #PetroleumAct #EnergyIndustry

Tolu Minerals Ltd (ASX:TOK) CEO Iain Macpherson joins Proactive’s Tylah Tully to discuss significant high-grade gold and silver results from diamond drilling at Taula prospect, 4.5 kilometres southeast of the Tolukuma Gold Mine in Papua New Guinea.

The results include 1 metre at 61.20 g/t gold and 1,979 g/t silver within a broader intersection of 4.8 metres at 22.79 g/t gold and 513.2 g/t silver.

These results suggest the potential extension of the gold vein system over a 1.5-kilometre strike length, open for further exploration to the north and south.

The company is now evaluating these results to update its mineral resource estimate.

Macpherson noted that these findings reinforced Tolu's strategy to leverage existing infrastructure and operational capabilities at Tolukuma, aiming to position it as a significant gold and silver producer.

The drilling program is Tolu's first outside the Tolukuma mining lease, validating geophysical exploration tools, including historical and recent 3D Induced Polarisation and Airborne Magneto Telluric surveys.

The drill rig has now returned to the Tolukuma mine site to seek further gold resources in a bid to extend the mine’s future operational capacity.

#ProactiveInvestors #ToluMinerals #ASX #GoldMining, #SilverDiscovery, #TolukumaProject, #PapuaNewGuinea, #HighGradeMinerals, #TaulaProspect, #ExplorationSuccess, #MiningUpdate, #GoldVeins, #DrillingResults, #MineralResources, #GeophysicalSurvey, #InducedPolarisation, #AirborneMagnetoTelluric, #MiningInfrastructure, #LifeOfMine, #StrikeLength, #PreciousMetals, #MiningExpansion

HeartCore Enterprises Inc CEO Sumitaka Kanno talked with Proactive's Stephen Gunnion about the company’s strong third-quarter performance and future outlook. The company achieved a record-breaking $17.9 million in revenue, marking a 281% growth. Kanno highlighted that its Go IPO business, which assists Japanese companies in listing on US stock exchanges, contributed about $14 million of this revenue. The company also reported net profit of $10 million.

Kanno shared updates on HeartCore’s software business, including the development of an AI-driven CMS platform and a shift toward multi-year licensing agreements. The company expects the fourth quarter to continue this growth trajectory, with projections to double last year's revenue.

"The good thing is, we can select good companies who have good revenue, good profit, or excellent customers," said Kanno, emphasizing their strong client pipeline and innovations in software as a service.

For more insights into HeartCore Enterprises’ plans and results, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe to our channel, and enable notifications for updates!

#HeartCoreEnterprises #IPO #RevenueGrowth #TechInnovation #AI #Q3Results #Investing #Proactive #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews